Drug Profile
H5N1 avian influenza vaccine intranasal - MedImmune/NIAID
Alternative Names: Avian flu vaccine - MedImmune/NIAID; H5N1 influenza vaccine - MedImmune/NIAID; MEDI-550; MEDI-566; Pandemic influenza vaccine - MedImmune/NIAIDLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator MedImmune Vaccines; National Institute of Allergy and Infectious Diseases
- Developer MedImmune Vaccines
- Class Influenza A virus H5N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Influenza A virus H5N1 subtype
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention) in USA (Intranasal)
- 01 Apr 2016 The Committee for Medicinal Products for Human Use recommends approval of Influenza-A virus H5N1 subtype vaccine for Influenza-A virus H5N1 subtype (Prevention) in European Union (Intranasal)
- 31 Dec 2015 Preregistration for Influenza-A virus H5N1 subtype(Prevention) in European Union (Intranasal) (AstraZeneca's pipeline, February 2016)